Efficacy of Temsirolimus after Previous Treatment with Sunitinib, Sorafenib or Everolimus in Advanced Renal Cell Cancer

Publisher： Karger

E-ISSN： 1423-0232|80|1-2|34-41

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.1-2, 2011-05, pp. : 34-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review

By Wong Michael K.   Yang Hongbo   Signorovitch James E.   Wang Xufang   Liu Zhimei   Liu Nathan S.   Qi Cynthia Z.   George Daniel J.  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 537-545

Informa Healthcare

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Safety and efficacy of sunitinib for advanced non‐clear cell renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 4, 2015-12 ,pp. : 328-333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-01 ,pp. : 16-18

Karger

Access to resources Recommend Favorite